GURUFOCUS.COM » STOCK LIST » Latin America » Brazil » BSP » Biogen Inc (BSP:BIIB34) » Definitions » Inventories, Raw Materials & Components
Switch to:

Biogen (BSP:BIIB34) Inventories, Raw Materials & Components

: R$2,252 Mil (As of Mar. 2023)
View and export this data going back to 2016. Start your Free Trial

Biogen's inventories, raw materials & components for the quarter that ended in Mar. 2023 was R$2,252 Mil.

Biogen's quarterly raw materials increased from Sep. 2022 (R$2,067 Mil) to Dec. 2022 (R$2,167 Mil) and increased from Dec. 2022 (R$2,167 Mil) to Mar. 2023 (R$2,252 Mil).

Biogen's annual raw materials increased from Dec. 2020 (R$1,620 Mil) to Dec. 2021 (R$1,977 Mil) and increased from Dec. 2021 (R$1,977 Mil) to Dec. 2022 (R$2,167 Mil).


Biogen Inventories, Raw Materials & Components Historical Data

The historical data trend for Biogen's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Raw Materials & Components
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 696.53 1,620.07 1,976.95 2,167.40

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Inventories, Raw Materials & Components Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,764.13 1,908.03 2,067.03 2,167.40 2,252.20

Biogen Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Biogen (BSP:BIIB34) Business Description

Biogen logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Inventories, Raw Materials & Components
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines